Страна: Канада
мова: англійська
Джерело: Health Canada
PILOCARPINE HYDROCHLORIDE
STERIMAX INC
N07AX01
PILOCARPINE
5MG
TABLET
PILOCARPINE HYDROCHLORIDE 5MG
ORAL
100
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0107358009; AHFS:
APPROVED
2013-02-26
_ _ _Pilocarpine Hydrochloride Tablets, USP Product Monograph _ _Page 1 of 30 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr PILOCARPINE HYDROCHLORIDE TABLETS, USP 5 MG TABLETS CHOLINOMIMETIC AGENT SteriMax Inc. 2770 Portland Drive Oakville, ON L6H 6R4 DATE OF REVISION: June 23, 2015 Submission Control No: 182910 _Pilocarpine Hydrochloride Tablets, USP Product Monograph _ _ Page 2 of 30_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 12 DOSAGE AND ADMINISTRATION ............................................................................. 12 OVERDOSAGE ............................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 13 STORAGE AND STABILITY ......................................................................................... 17 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 17 PART II: SCIENTIFIC INFORMATION ............................................................................... 19 PHARMACEUTICAL INFORMATION ......................................................................... 19 CLINICAL TRIALS .............................................................................. Прочитайте повний документ